JX 929

Drug Profile

JX 929

Alternative Names: JX-929; vvDD-CDSR

Latest Information Update: 28 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Jennerex
  • Developer University of Pittsburgh
  • Class Antineoplastics; Oncolytic viruses
  • Mechanism of Action Cytosine deaminase modulators; Epidermal growth factor receptor modulators; Somatostatin receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 28 Apr 2016 Phase I development is ongoing in USA (IV & Intratumoural)
  • 19 Jun 2014 SillaJen is now called SillaJen Biotherapeutics
  • 17 Mar 2014 Jennerex has been acquired by SillaJen
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top